Yichang drugmaker wins city's first national patent award
2025-06-08 20:06:51
By Hu Yikai.
Yichang HEC Changjiang Pharmaceutical Co., Ltd. has won the city’s first China Patent Gold Award for its pediatric oseltamivir phosphate granules, an innovative flu treatment.
The medication, recognized by China's National Health Commission as a primary treatment for H1N1 and H7N9 influenza, earned top honors for both its technological excellence and industrial impact, according to a June 5 announcement from China’s National Intellectual Property Administration.
"Kewei" oseltamivir phosphate granules.
Oseltamivir is a key antiviral drug for preventing and treating influenza. As the global leader in oseltamivir production, Yichang HEC Changjiang Pharmaceutical has long been committed to the development of this product. Oseltamivir phosphate granules remain the company's core patented product.
Researchers working in the lab.
The firm has built a complete supply chain, meeting over 90 percent of domestic demand. The annual production capacity of this granule formulation reaches 4 billion packets. The "Kewei" product series achieved sales revenue of 6.3 billion yuan (US$880 million) in 2023.
Building on this core patent, Yichang HEC has also filed five additional invention patents related to oseltamivir, further consolidating its technological advantages and market position.
Photo from Yidu Convergence Media.
Yichang HEC Changjiang Pharmaceutical Co., Ltd. has won the city’s first China Patent Gold Award for its pediatric oseltamivir phosphate granules, an innovative flu treatment.
The medication, recognized by China's National Health Commission as a primary treatment for H1N1 and H7N9 influenza, earned top honors for both its technological excellence and industrial impact, according to a June 5 announcement from China’s National Intellectual Property Administration.
"Kewei" oseltamivir phosphate granules.Oseltamivir is a key antiviral drug for preventing and treating influenza. As the global leader in oseltamivir production, Yichang HEC Changjiang Pharmaceutical has long been committed to the development of this product. Oseltamivir phosphate granules remain the company's core patented product.
Researchers working in the lab.The firm has built a complete supply chain, meeting over 90 percent of domestic demand. The annual production capacity of this granule formulation reaches 4 billion packets. The "Kewei" product series achieved sales revenue of 6.3 billion yuan (US$880 million) in 2023.
Building on this core patent, Yichang HEC has also filed five additional invention patents related to oseltamivir, further consolidating its technological advantages and market position.
Photo from Yidu Convergence Media.
